GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 30, 2024 – 6.30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), reported today its full-year results for the […]
GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting
Geneva, Switzerland, March 20, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its […]
GeNeuro announces the availability of a prospectus for the listing of new shares on Euronext Paris
Geneva, Switzerland, February 2, 2024 – 20:00 CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO) (the “Company”), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, COVID long or post-COVID), announces that on February […]
GeNeuro announces a successful €5 million private placement
Geneva, Switzerland, February 2, 2024 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the successful completion of a €5 million capital […]
GeNeuro launches an offering with a commitment to subscribe by existing shareholders and announces its cash position at December 31, 2023
Geneva, Switzerland, February 1, 2024– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announces the launch of a private placement of ordinary shares […]
GeNeuro names Anke Post as Chief Medical Officer, following retirement of David Leppert who becomes a consultant to GeNeuro
Geneva, Switzerland, January 5, 2024 – 6pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announces the appointment of Anke Post, MD, PhD […]